The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)
Clinical trial NCT02510261 · COMPLETED
Trial details
- NCT number
- NCT02510261
- Sponsor
- Alnylam Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-07-16
- Primary completion
- 2022-11-23
- Enrollment
- 211
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.